Valeant adds shareholder John Paulson to board

Ivan Schwartz
June 19, 2017

Its down 0.10, from 0.88 in 2016Q3. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)'s total market worth is $4.53B along with 341.19M outstanding shares.

Other hedge funds have also recently added to or reduced their stakes in the company. Royal Bank Of Canada reduced their target price on shares of Valeant Pharmaceuticals International to $21.00 in a report on Wednesday, March 1st. 14,674,829 shares of the stock traded hands. Jpmorgan Chase Com stated it has 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Armstrong Henry H Associate Inc reported 93,748 shares stake. Stanley Mngmt Lc owns 155,300 shares. Pension Serv reported 0.03% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Marathon Trading Invest Mgmt Ltd Liability Corp accumulated 0.09% or 56,098 shares. 484,618 are owned by Cibc Asset Mngmt Incorporated. Dimensional Fund Advisors L P, a Texas-based fund reported 576,634 shares. Continental Advsrs Ltd Co reported 117,300 shares. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the Zacks' consensus estimate of $0.87 by $1.93. Illinois-based Peak6 Investments Limited Partnership has invested 0.01% in Valeant Pharmaceuticals Intl Inc (TSE:VRX). Citigroup Inc holds 137,268 shares or 0% of its portfolio. Tiaa Cref Limited Liability Corporation owns 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 479,756 shares.

Since March 13, 2017, it had 3 insider purchases, and 1 insider sale for $166.26 million activity. ValueAct Holdings - L.P. also bought $32.47M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares.

Father's Day Gift Guide: From shaving sets to backpacks and desi pickles
During this brief window of opportunity, babies' brains can make up to 1,000 new connections every single second. Today's is Father's Day , a time to say thank you to those who have play the important role of dad.

Supermarket arms race: Nisa gears up for member vote over Sainsbury's buyout
It followed Tesco's proposed £3.7bn acquisition of Booker Group, the food distributor, among other recent moves in the sector. If the Nisa board recommends the offer, it would require the backing of at least 50% of Nisa's shopkeeper members.

Brooks Koepka caps record week with title
If anything, the better story might have been diminutive 30-year-old lefty and University of Georgia product Brian Harman . He followed with birdies at 15 and 16 to suddenly widen his gap to four shots and close in on the Open championship.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 20,000 shares of the stock in a transaction that occurred on Thursday, May 11th. In a transaction dated March 14, 2017, the shares were bought at an average price of $10.72, giving away a sum of $257,280. On Monday, March 13 the insider Pershing Square Capital Management - L.P. sold $199.26 million.

Cantor Fitzgerald analyst initiated coverage on Valeant Pharmaceuticals International VRX (NYSE:VRX) with a $18.00 PT and "Overweight" rating. The TP is exactly $18.00. Guggenheim restated a "buy" rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, February 28th. Therefore 24% are positive. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $32.74. $72.29's average target is 471.01% above currents $12.66 stock price. On average, analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year. On Wednesday, October 14 the stock rating was maintained by Scotia Capital with "Sector Outperform". The firm has "Market Perform" rating by BMO Capital Markets given on Wednesday, June 29. The stock has "Outperform" rating by RBC Capital Markets on Monday, December 14. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Friday, May 5.

Among 4 analysts covering Lundin Gold (TSE:LUG), 4 have Buy rating, 0 Sell and 0 Hold. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned "Buy" rating by Bank of America on Wednesday, September 30. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, October 27. The firm has made a decision to set a Overweight rating along with a $18.00, adding 42.18 % to the target. The stock was last seen 4.46% higher, reaching at $12.66 on June 16, 2017. It has underperformed by 65.21% the S&P500. Paulson & Co. Inc. owns $245.41 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.54% of the company's market cap and approximately 10.87% of the institutional ownership. The stock's market capitalization is $4.22 billion. The Company is involved in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. It now has negative earnings. The Company operates through two segments: Developed markets and Emerging markets.

Other reports by GizPress

Discuss This Article